Brief: Maat Pharma Announces Positive Topline Results From Phase 3 Ares Study

Maat Pharma SA

08/01/2025 18:32

Jan 9 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE
PIVOTAL
PHASE 3 ARES STUDY EVALUATING MAAT013 IN ACUTE GRAFT-VERSUS-HOST
DISEASE
    * MAAT PHARMA SA: COMPANY ANTICIPATES MAA SUBMISSION IN
EUROPE IN
MID-2025, EARLIER THAN INITIALLY PLANNED
    * MAAT PHARMA SA - STUDY MEETS PRIMARY ENDPOINT WITH 62%
GI-ORR AT
DAY 28


 ((Reuters.Briefs@thomsonreuters.com;;))